These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34080646)

  • 1. IL13Rα2‑ and EGFR‑targeted pseudomonas exotoxin potentiates the TRAIL‑mediated death of GBM cells.
    Karakaş N; Stuckey D; Revai-Lechtich E; Shah K
    Int J Mol Med; 2021 Jul; 48(1):. PubMed ID: 34080646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
    Han J; Yang L; Puri RK
    J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitizing TRAIL‑resistant A549 lung cancer cells and enhancing TRAIL‑induced apoptosis with the antidepressant amitriptyline.
    Zinnah KMA; Park SY
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
    Kioi M; Kawakami K; Puri RK
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
    van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL13 Fused
    Uludağ D; Karakaş N
    Anticancer Res; 2021 Jul; 41(7):3471-3480. PubMed ID: 34230142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.
    Horita H; Thorburn J; Frankel AE; Thorburn A
    J Neurooncol; 2009 Nov; 95(2):175-184. PubMed ID: 19449148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas.
    Burton TR; Henson ES; Azad MB; Brown M; Eisenstat DD; Gibson SB
    Cell Death Dis; 2013 Apr; 4(4):e587. PubMed ID: 23579274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.
    Sato Y; Vatsan R; Joshi BH; Husain SR; Puri RK
    Curr Mol Med; 2024; 24(6):758-770. PubMed ID: 36999709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor 5 upregulation.
    Zinnah KMA; Seol JW; Park SY
    Int J Mol Med; 2020 Aug; 46(2):795-805. PubMed ID: 32626921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
    Kioi M; Seetharam S; Puri RK
    Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.
    Redjal N; Zhu Y; Shah K
    Stem Cells; 2015 Jan; 33(1):101-10. PubMed ID: 25186100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
    Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
    Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
    Park D; Ha IJ; Park SY; Choi M; Lim SL; Kim SH; Lee JH; Ahn KS; Yun M; Lee SG
    J Nat Prod; 2016 Feb; 79(2):317-23. PubMed ID: 26829656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
    Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
    Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro.
    Gholipour Z; Fooladi AAI; Parivar K; Halabian R
    Toxicol In Vitro; 2023 Oct; 92():105651. PubMed ID: 37482138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.